Department of Transplantation, Hopital Edouard Herriot, Lyon, France.
Transplantation. 2010 Dec 27;90(12):1590-4. doi: 10.1097/TP.0b013e3181ff1472.
The International Registry on Hand and Composite Tissue Transplantation was founded in May 2002, and the analysis of all cases with follow-up information up to July 2010 is presented here.
From September 1998 to July 2010, 49 hands (17 unilateral and 16 bilateral hand transplantations, including 1 case of bilateral arm transplantation) have been reported, for a total of 33 patients. They were 31 men and 2 women (median age 32 years). Time since hand loss ranged from 2 months to 34 years, and in 46% of cases, the level of amputation was at wrist. Immunosuppressive therapy included tacrolimus, mycophenolate mofetil, sirolimus, and steroids; polyclonal or monoclonal antibodies were used for induction. Topical immunosuppression was also used in several cases. Follow-up ranges from 1 month to 11 years.
One patient died on day 65. Three patients transplanted in the Western countries have lost their graft, whereas until September 2009, seven hand grafts were removed for noncompliance to the immunosuppressive therapy in China. Eighty-five percent of recipients experienced at least one episode of acute rejection within the first year, and they were reversible when promptly treated. Side effects included opportunistic infections, metabolic complications, and malignancies. All patients developed protective sensibility, 90% of them developed tactile sensibility, and 82.3% also developed a discriminative sensibility. Motor recovery enabled patients to perform most daily activities.
Hand transplantation is a complex procedure, and its success is based on patient's compliance and his or her careful evaluation before and after transplantation.
国际手与复合组织移植注册研究成立于 2002 年 5 月,本研究分析了截至 2010 年 7 月所有随访信息完整的病例。
1998 年 9 月至 2010 年 7 月,共报道了 49 例手移植(17 例为单侧,16 例为双侧,包括 1 例双侧臂移植),总计 33 例患者。其中男性 31 例,女性 2 例(中位年龄 32 岁)。手丧失时间为 2 个月至 34 年,46%的患者截肢平面在腕关节。免疫抑制治疗包括他克莫司、霉酚酸酯、西罗莫司和皮质类固醇;诱导治疗采用多克隆或单克隆抗体。数例患者采用局部免疫抑制治疗。随访时间为 1 个月至 11 年。
1 例患者术后第 65 天死亡。3 例在西方国家接受移植的患者手已丢失,而截至 2009 年 9 月,在中国有 7 例因不能耐受免疫抑制治疗而去除移植手。85%的受者在术后 1 年内至少经历了 1 次急性排斥反应,及时治疗后均为可逆性的。副作用包括机会性感染、代谢并发症和恶性肿瘤。所有患者均恢复保护性感觉,90%的患者恢复触觉,82.3%的患者恢复分辨觉。运动功能的恢复使患者能够进行大多数日常活动。
手移植是一个复杂的过程,成功依赖于患者对治疗的配合和移植前后的仔细评估。